Drug‐disease interactions: reduced β‐adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat
- 1 May 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (2) , 286-294
Abstract
Inflammation may influence response to pharmacotherapy. We investigated the effect of inflammation on response to sotalol, a β‐adrenergic receptor and potassium channel antagonist. Racemic sotalol (40 mg kg−1) was administered to healthy, acutely (interferonα 2a‐induced) and chronically (Mycobacterium butyricum‐induced adjuvant arthritis) inflamed male Sprague‐Dawley rats (n=4 – 6/group). Another group of interferon‐treated rats received 3 mg kg−1 of anti‐TNF antibody infliximab. Electrocardiogram (ECG) recorded and plasma sotalol concentration monitored for 6 h. The study was repeated in acutely inflamed rats following administration of stereochemically pure individual sotalol enantiomers [40 mg kg−1 S (potassium channel blocker) or 20 mg kg−1 R (β‐adrenergic/potassium channel blocker)]. Chronic arthritis was readily evident. Acute arthritis was associated with elevated segmented neutrophils and increased plasma nitrite and tumour necrosis factor (TNF) concentrations. Sotalol affected ECG in all rats. In both inflamed groups, however, response to sotalol in prolongation of QT interval (potassium channel sensitivity) was reduced. The effect of PR interval (β‐adrenergic activity) was also reduced following administration of the racemate and R‐enantiomer. No significant differences in pharmacokinetics were observed between control and inflamed rats. Infliximab reduced nitrite and TNF concentrations and reversed the effect of acute inflammation on both PR and QT intervals. The reduced electrocardiographic responses to sotalol is likely due to the influence of inflammation on the action of the drug on both β‐adrenergic and potassium channel receptors secondary to over‐expression of pro‐inflammatory cytokines and/or nitric oxide. Our observation may have therapeutic consequences in all conditions where inflammatory mediators are increased. British Journal of Pharmacology (2001) 133, 286–294; doi:10.1038/sj.bjp.0704067Keywords
This publication has 39 references indexed in Scilit:
- InfliximabDrugs, 2000
- A High Plasma Concentration of TNF- Is Associated With Dementia in CentenariansThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 1999
- Relationship between K+ channel down‐regulation and [Ca2+]i in rat ventricular myocytes following myocardial infarctionThe Journal of Physiology, 1999
- Tyrosine kinase-dependent modulation by interferon-α of the ATP-sensitive K+current in rabbit ventricular myocytesFEBS Letters, 1999
- Endotoxin and Tumor Necrosis FactorαExert a Similar Proinflammatory Effect in Neonatal Rat Cardiomyocytes, but have Different Cardiodepressant Profiles,Journal of Molecular and Cellular Cardiology, 1998
- Predicting Effective Drug Concentrations for Individual PatientsClinical Pharmacokinetics, 1998
- Age-Dependent Changes in the β-Adrenoceptor—G-Protein(s)—Adenylyl Cyclase System in Human Right AtriumJournal of Cardiovascular Pharmacology, 1995
- Interferon- Enhances Neutrophil Respiratory Burst Responses To Stimulation With Influenza A Virus And FmlpThe Journal of Infectious Diseases, 1994
- Altered β-Adrenergic Sensitivity and Protein Binding to 1-Propranolol in the ElderlyJournal of Cardiovascular Pharmacology, 1990
- Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α1Acid GlycoproteinNew England Journal of Medicine, 1978